vs

Side-by-side financial comparison of Aterian, Inc. (ATER) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Aterian, Inc. is the larger business by last-quarter revenue ($15.1M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). Aterian, Inc. runs the higher net margin — -52.5% vs -1398.3%, a 1345.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -38.5%). Aterian, Inc. produced more free cash flow last quarter ($-1.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -13.5%).

Aterian, Inc. is a technology-enabled consumer products company that leverages artificial intelligence and data analytics to identify market demand, develop, source and distribute a wide portfolio of affordable goods spanning home improvement, wellness, personal care, pet supplies and outdoor recreation. It primarily sells its products through leading global e-commerce platforms, with core markets covering North America and Europe.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ATER vs RNA — Head-to-Head

Bigger by revenue
ATER
ATER
1.2× larger
ATER
$15.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+472.5% gap
RNA
434.0%
-38.5%
ATER
Higher net margin
ATER
ATER
1345.8% more per $
ATER
-52.5%
-1398.3%
RNA
More free cash flow
ATER
ATER
$155.8M more FCF
ATER
$-1.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-13.5%
ATER

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ATER
ATER
RNA
RNA
Revenue
$15.1M
$12.5M
Net Profit
$-7.9M
$-174.4M
Gross Margin
56.1%
Operating Margin
-51.1%
-1513.5%
Net Margin
-52.5%
-1398.3%
Revenue YoY
-38.5%
434.0%
Net Profit YoY
-512.2%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATER
ATER
RNA
RNA
Q4 25
$15.1M
Q3 25
$19.0M
$12.5M
Q2 25
$19.5M
$3.8M
Q1 25
$15.4M
$1.6M
Q4 24
$24.6M
$3.0M
Q3 24
$26.2M
$2.3M
Q2 24
$28.0M
$2.0M
Q1 24
$20.2M
$3.5M
Net Profit
ATER
ATER
RNA
RNA
Q4 25
$-7.9M
Q3 25
$-2.3M
$-174.4M
Q2 25
$-4.9M
$-157.3M
Q1 25
$-3.9M
$-115.8M
Q4 24
$-1.3M
$-102.3M
Q3 24
$-1.8M
$-80.4M
Q2 24
$-3.6M
$-70.8M
Q1 24
$-5.2M
$-68.9M
Gross Margin
ATER
ATER
RNA
RNA
Q4 25
56.1%
Q3 25
56.1%
Q2 25
54.3%
Q1 25
61.4%
Q4 24
63.4%
Q3 24
60.3%
Q2 24
60.4%
Q1 24
65.1%
Operating Margin
ATER
ATER
RNA
RNA
Q4 25
-51.1%
Q3 25
-10.7%
-1513.5%
Q2 25
-23.1%
-4448.7%
Q1 25
-24.1%
-8360.9%
Q4 24
-6.5%
-4069.6%
Q3 24
-6.6%
-4200.9%
Q2 24
-11.5%
-4040.4%
Q1 24
-26.1%
-2178.6%
Net Margin
ATER
ATER
RNA
RNA
Q4 25
-52.5%
Q3 25
-12.0%
-1398.3%
Q2 25
-25.0%
-4089.3%
Q1 25
-25.4%
-7360.0%
Q4 24
-5.3%
-3439.5%
Q3 24
-6.8%
-3441.7%
Q2 24
-13.0%
-3461.8%
Q1 24
-25.5%
-1943.4%
EPS (diluted)
ATER
ATER
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATER
ATER
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$4.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.2M
$1.9B
Total Assets
$29.6M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATER
ATER
RNA
RNA
Q4 25
$4.9M
Q3 25
$7.6M
$350.2M
Q2 25
$10.5M
$243.9M
Q1 25
$14.3M
$254.2M
Q4 24
$18.0M
$219.9M
Q3 24
$16.1M
$370.2M
Q2 24
$20.3M
$575.8M
Q1 24
$17.5M
$471.4M
Stockholders' Equity
ATER
ATER
RNA
RNA
Q4 25
$15.2M
Q3 25
$22.6M
$1.9B
Q2 25
$24.3M
$1.2B
Q1 25
$27.0M
$1.3B
Q4 24
$30.0M
$1.4B
Q3 24
$30.6M
$1.5B
Q2 24
$30.9M
$1.2B
Q1 24
$33.0M
$830.9M
Total Assets
ATER
ATER
RNA
RNA
Q4 25
$29.6M
Q3 25
$40.1M
$2.1B
Q2 25
$45.4M
$1.4B
Q1 25
$49.8M
$1.5B
Q4 24
$49.5M
$1.6B
Q3 24
$52.1M
$1.6B
Q2 24
$59.9M
$1.3B
Q1 24
$55.7M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATER
ATER
RNA
RNA
Operating Cash FlowLast quarter
$-1.0M
$-156.2M
Free Cash FlowOCF − Capex
$-1.0M
$-156.9M
FCF MarginFCF / Revenue
-6.9%
-1257.6%
Capex IntensityCapex / Revenue
0.0%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATER
ATER
RNA
RNA
Q4 25
$-1.0M
Q3 25
$-1.6M
$-156.2M
Q2 25
$-4.4M
$-199.7M
Q1 25
$-3.9M
$-124.8M
Q4 24
$-9.0K
$-99.9M
Q3 24
$-722.0K
$-65.6M
Q2 24
$2.9M
$-65.0M
Q1 24
$-6.0K
$-70.4M
Free Cash Flow
ATER
ATER
RNA
RNA
Q4 25
$-1.0M
Q3 25
$-1.6M
$-156.9M
Q2 25
$-4.4M
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$2.9M
$-65.5M
Q1 24
$-42.0K
$-71.3M
FCF Margin
ATER
ATER
RNA
RNA
Q4 25
-6.9%
Q3 25
-8.4%
-1257.6%
Q2 25
-22.7%
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
10.3%
-3204.6%
Q1 24
-0.2%
-2012.3%
Capex Intensity
ATER
ATER
RNA
RNA
Q4 25
0.0%
Q3 25
0.2%
5.7%
Q2 25
0.0%
86.9%
Q1 25
0.0%
238.6%
Q4 24
0.0%
131.7%
Q3 24
0.0%
72.9%
Q2 24
0.0%
26.0%
Q1 24
0.2%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATER
ATER

Sales Channel Directly To Consumer$13.1M87%
Heating Cooling And Air Quality$2.1M14%

RNA
RNA

Segment breakdown not available.

Related Comparisons